RxDoctor Payments Data

Colleen Diering

Adult Health · Virginia Beach, VANPI 1982722153

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,045 of the $12,960 with a category attached, or 69.8%. AbbVie accounts for 89.3% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $6,240, 6.2 times the $1,012 reported in 2021. Among adult health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,960in general payments, 2019–2025

Across 231 payments — averaging $56.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$12K
  • Novartis$380
  • Teva Pharmaceuticals USA, Inc.$134
  • Pfizer$134
  • Biohaven Pharmaceutical Holding Company Ltd.$104
  • Lilly USA, LLC$79
  • plus $550 from 16 others

What the payments were for

  • Speaking & faculty fees$9,04570%
  • Travel & lodging$2472%
  • Food & beverage$3,66828%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,960 in reported general payments places this provider in the 95th percentile of 368 adult health providers in Virginia.

See all adult health providers in Virginia

Medicare billing

Part B allowed, 2024
$17,952
Medicare patients
93
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant31$46,041
Nurtec OdtRimegepant Sulfate31$41,619
QuliptaAtogepant21$33,719
Emgality SyringeGalcanezumab-Gnlm17$26,847
Emgality PenGalcanezumab-Gnlm14$10,638
Sumatriptan Succinate37$4,635
Gabapentin48$657
RizatriptanRizatriptan Benzoate14$285
Topiramate24$145
Tizanidine Hcl23$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$11,579$79,76052 claims
PfizerNurtec Odt$134$41,61931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 368 adult health providers in Virginia.

Other adult health in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →